PHARMACEUTICALS Corporate Environmental and Sustainability Reporting PACIFIC SUSTAINABILITY INDEX: SCORES

Total Page:16

File Type:pdf, Size:1020Kb

Load more

CLAREMONT MCKENNA COLLEGE ROBERTS ENVIRONMENTAL CENTER 2003 FORTUNE GLOBAL 500 AND FORTUNE 1000 PHARMACEUTICALS Corporate Environmental and Sustainability Reporting PACIFIC SUSTAINABILITY INDEX: SCORES J. Emil Morhardt Andrea R. Bravo Mary Beth Houlihan Sara Leverette Benjamin A. Schachter Marta E. Young Morhardt, J. E., A. R. Bravo, M. B. Houlihan, S. Leverette, B. A. Schachter, and M. E. Young (2004) Pharmaceuticals—Corporate Emnvironmental and Sustainability Reporting: Pacific Sustainability Index Scores. Claremont, CA., Roberts Environmental Center, Claremont McKenna College Price: $20.00 www.roberts.mckenna.edu 2003 Pharmaceutical Industry Report 1 CLAREMONT MCKENNA COLLEGE ROBERTS ENVIRONMENTAL CENTER Contents Corporate Environmental and Sustainability Reporting . .3 Pharmaceutical Company Rankings . 3 The Pacific Sustainability Index (PSI) . 4 The PSI Scoring System . .4 Environmental vs. Social Scores . .4 Intent, Reporting, and Performance. 4 More Environmental than Social Reporting . .4 Distribution of Possible PSI Scores . 5 Overall PSI Scores . 5 Environmental Intent Scores . .6 Environmental Reporting Scores . .6 Environmental Performance Scores . .7 Combined Environmental Scores . 7 Social Intent Scores . 8 Publications from Roberts Environmental Center Social Reporting Scores . .8 Social Performance Scores . .9 Combined Social Scores . .10 The Roberts Environmental Center publishes analyses of corporate environmental and social reports—together called Analysts’ Comments . 10 sustainability reports—to the web and in special reports. Abbott Laboratories . 10 Allergan . 10 We also write books about environmental and sustainability Amgen . .10 reporting, the first of which is Clean, Green, and Read All AstraZeneca . 10 Over: Ten Rules for Corporate Environmental and Aventis . 10 Sustainability Reporting, available from ASQ Press, and Barr Laboratories . 10 publish articles in academic technical journals. Biogen Pharmaceuticals . 10 Bristol-Myers Squibb . 10 For more information please visit our web site at: Chiron Pharmaceuticals . .10 www.roberts.mckenna.edu. Eli Lilly and Company . 10 Forest Laboratories . .10 To order additional copies of this reportreport, or to obtain Genzyme Pharmaceuticals . 10 multiple-copy discount rates, please write, email, or call: GlaxoSmithKline . 10 IVAX. 11 Dr. J. Emil Morhardt, Director Johnson & Johnson . 11 Roberts Environmental Center King Pharmaceuticals . 11 Claremont McKenna College Merck & Co., Inc. .11 925 N. Mills Avenue Novartis . 11 Claremont, CA 91711-5916 Pfizer . .11 USA Pharmacia Corporation . 11 Roche . 11 909-621-8190 Schering-Plough Corporation . 11 [email protected] Watson Pharmaceuticals . .11 Wyeth . 11 The goal of corporate report analysis conducted by the Roberts Environ- mental Center is to acquaint students with environmental and social issues The Roberts Environmental Center . 12 facing the world’s industries, and the ways in which industry approaches and resolves these issues. This report is a work product of the Fall 2003 Claremont McKenna College . 12 Environment, Economics and Politics Clinic. Copyright 2004 © by J. Emil The Claremont Colleges . .12 Morhardt. All rights reserved. 2 2003 Pharmaceutical Industry Report www.roberts.mckenna.edu CLAREMONT MCKENNA COLLEGE ROBERTS ENVIRONMENTAL CENTER 2003 FORTUNE GLOBAL 500 AND FORTUNE 1000 PHARMACEUTICALS Corporate Environmental and Sustainability Reporting During the past decade, large manufacturing corpora- This report covers all of the companies in the phar- tions have begun to report voluntarily on the environ- maceutical sector of the 2003 Fortune Global 500 mental issues affecting their companies and on how and Fortune 1000 lists, whether or not they produced they deal with them. The addition of social issues to formal environmental or sustainability reports. It is these reports has resulted in some firms designating based on environmental and social information them “sustainability reports”. Some firms produce available on their web sites in October 2003. The these reports yearly, others only occasionally, and quality of their environmental and social reporting some not at all. We obtain these reports and any was characterized by students in the Claremont additional information exclusively from corporate Colleges using the Roberts Environmental Center’s web sites. Pacific Sustainability Index (PSI). The overall company PSI scores rank as follows: Pharmaceutical Company PSI Rankings 1 Aventis 1 Bristol-Myers Squibb Company 1 GlaxoSmithKline 4 Novartis 5 Johnson & Johnson 6 Abbott Laboratories 7 AstraZeneca 8 Merck & Co., Inc. 9 Pharmacia Corporation 9 Wyeth 11 Allergan 12 Pfizer Inc. 12 Roche Group 14 Eli Lilly and Company 15 Chiron 15 King Pharmaceuticals 17 Amgen 17 IVAX 19 Biogen 19 Forest Laboratories 19 Schering-Plough Corporation 22 Barr Laboratories, Inc. 22 Genzyme 22 Watson Pharmaceuticals www.roberts.mckenna.edu 2003 Pharmaceutical Industry Report 3 CLAREMONT MCKENNA COLLEGE ROBERTS ENVIRONMENTAL CENTER The Pacific Sustainability Index (PSI)1 THE PSI SCORING SYSTEM OVERALL SCORE The Pacific Sustainability Index (PSI) comprises a list of The PSI has a total of 140 topics, 80 of them on 140 topics that should be addressed in corporate environ- environmental issues and 60 on social issues. The mental and sustainability reports. The topics were derived overall score is the percentage of the maximum from the ISO 14000 family of international environmental possible score on all 140 topics. standards, from reporting guidelines, including those of the Global Reporting Initiative (GRI), and from a variety ENVIRONMENTAL INTENT SCORE of other sources. The philosophy of the PSI is described in detail in our book, Clean, Green, and Read All Over, Scores from PSI topics 1-27, 54, and 55. These published by and available from the American Society for topics reflect a firm’s comittment to environmental Quality Press2. Each of the topics has a maximum score of reporting. either two or three points. The overall scores are pre- sented in the graph on page five, and are used to create the ENVIRONMENTAL REPORTING SCORE ranking on page three. The overall score is calculated as a Scores from PSI topics 28-53. These topics reflect percentage of the maximum possible score. reporting of environmental performance without ENVIRONMENTAL VS. SOCIAL SCORES reflecting the quality of that performance. In addition to the overall score, we have subsetted the PSI into its environmental and social components and ENVIRONMENTAL PERFORMANCE SCORE reported each of these independently in graphs on pages Scores from PSI topics 56-80. These scores reflect six through nine. The subsetted scores are also calculated improved environmental performance, or perfor- as percent of maximum possible score for each subset, mance better than the average of a firm’s peers, or and have been arranged in the same rank order as the both. overall scores on page five. COMBINED ENVIRONMENTAL SCORE INTENT, REPORTING, AND PERFORMANCE Scores for all 80 environmental topics in the three Both environmental and social subsets of scores reflect intent, reporting, and performance. Intent scores are categories above. derived from topics in the PSI that reflect a stated willing- ness to perform well, to monitor that performance, and to SOCIAL INTENT SCORE report it. Reporting scores reflect presentation in the Scores from PSI questions 81-108, 124, and 125. report of data on specific environmental and social topics, They reflect a firm’s committment to social report- but not on how good that performance was—they indicate ing. transparency in reporting independent of success in making improvements. Performance scores reflect better SOCIAL REPORTING SCORE performance on specific environmental and social topics since the previous reporting period, better performance Scores from PSI questions 109-123, reflecting than peer companies, or both. amount of reporting of social performance without reflecting the quality of that performance. MORE ENVIRONMENTAL THAN SOCIAL REPORTING Inspection of the subsets shows that more companies SOCIAL PERFORMANCE SCORE report environmental information than report social Scores from PSI topics 126-140. These scores reflect information—that is, more are producing purely environ- improved social performance, or performance better mental reports than are producing sustainability reports— than the average of a firm’s peers, or both. and that the scores for environmental and social perfor- mance are far lower than those for either intent or report- COMBINED SOCIAL SCORE ing. Scores for all 60 social topics in the three categories 1PSI scoring sheets are available on our web site above. 2http://www.qualitypress.asq.org/perl/catalog.cgi?item=H1145 4 2003 Pharmaceutical Industry Report www.roberts.mckenna.edu CLAREMONT MCKENNA COLLEGE ROBERTS ENVIRONMENTAL CENTER Distribution of Possible PSI Scores The pie diagram to the right shows the quantitative ENTA distribution of possible points for the 140 topics in ONM L T IR O V PI the PSI scoring system. Environmental topics make N Environmental C E S up a little more than half of the total and social Reporting topics the remainder. Environmental and social intent topics make up 41 percent, reporting topics make up 24 percent, and performance topics make up 35 Environmental Environmental Intent Performance percent of the total possible score. Two thirds of the possible performance score requires that firms Social compare their performance to that of their peers and Social Performance
Recommended publications
  • Appendix a 2016 Financial Report Financial Review Pfizer Inc

    Appendix a 2016 Financial Report Financial Review Pfizer Inc

    Appendix A 2016 Financial Report Financial Review Pfizer Inc. and Subsidiary Companies GLOSSARY OF DEFINED TERMS Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2016 Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this 2016 Financial Report, most of which are explained or defined below: 2016 Financial Report This Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 2016 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2016 AAV Adeno-Associated Virus ABO Accumulated postretirement benefit obligation ACA (Also referred to as U.S. U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Healthcare Legislation) Act. ACIP Advisory Committee on Immunization Practices ALK anaplastic lymphoma kinase Allergan Allergan plc Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us AM-Pharma AM-Pharma B.V. Anacor Anacor Pharmaceuticals, Inc. Astellas Astellas Pharma U.S. Inc. ASU Accounting Standards Update ATM-AVI aztreonam-avibactam Bamboo Bamboo Therapeutics, Inc. Baxter Baxter International Inc. BMS Bristol-Myers Squibb Company CDC U.S. Centers for Disease Control and Prevention Cellectis Cellectis SA Celltrion Celltrion Inc. and Celltrion Healthcare,
  • [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical

    [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical

    This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
  • Health Advisory

    Health Advisory

    Health Advisory July 2, 2021 • Information for Pierce County Healthcare Providers Communicable Disease Control Communicable Disease Control • (253) 649-1412 3629 S. D St. • Tacoma, WA 98418 (253) 649-1412 • (253) 649-1358 (fax) COVID-19 Updates for Providers Requested actions • Be aware Washington State Department of Health (DOH) issued a behavioral health provider alert about Fourth of July celebrations and other summertime gatherings. The alert asks providers to give patients information about safe social behaviors and the potential negative effects of impulsive behaviors following the state’s full reopening and the misperception that the COVID-19 pandemic has ended. • Be aware the U.S. Food and Drug Administration (FDA) updated the following Emergency Use Authorization (EUA) fact sheets to include the possible risk of pericarditis and myocarditis following vaccination: o Pfizer fact sheet for healthcare providers. o Pfizer fact sheet for patients. o Moderna fact sheet for healthcare providers. o Moderna fact sheet for patients. • Continue to report any case of myocarditis and pericarditis among people who received COVID-19 mRNA vaccine within the last 2 weeks. o Promptly report cases to the U.S. Vaccine Adverse Events Reporting System (VAERS). o Report cases to the Health Department’s 24-hour reporting line at (253) 649-1413. Include vaccine manufacturer, vaccine lot number, vaccination date, dose number, patient gender, age and history of prior SARS-CoV-2 infection. • Be aware the FDA extended the shelf life of Janssen (Johnson & Johnson) COVID-19 vaccine from 3 months to 4½ months. Visit Janssen’s lot expiry checker to determine the updated expiration of your vaccine.
  • 1 UNITED STATES DISTRICT COURT DISTRICT of MINNESOTA Shirley

    1 UNITED STATES DISTRICT COURT DISTRICT of MINNESOTA Shirley

    CASE 0:10-cv-01821-JNE-JJK Document 65 Filed 04/05/11 Page 1 of 5 UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA Shirley Venus Shannon, Plaintiff, v. Civil No. 10-1821 (JNE/JJK) ORDER Baxter Healthcare Corporation, Hospira, Inc., and Abbott Laboratories, Inc., Defendants. In April 2010, Shirley Venus Shannon brought this action against Eli Lilly & Company and several unidentified entities. In October 2010, she filed an Amended Complaint against Baxter Healthcare Corporation, Hospira, Inc., and Abbott Laboratories, Inc. Abbott Laboratories and Hospira moved to dismiss the case for improper venue, see Fed. R. Civ. P. 12(b)(3); moved to dismiss the case for failure to state a claim upon which relief can be granted, see Fed. R. Civ. P. 12(b)(6); and moved to transfer the case to the United States District Court for the Northern District of Illinois, Eastern Division, see 28 U.S.C. § 1404(a) (2006). After answering, Baxter Healthcare joined the motions of Abbott Laboratories and Hospira. Baxter Healthcare did not separately submit memoranda of law. Shannon opposed the motions, but she asserted that the case should be transferred to the United States District Court for the Western District of Tennessee, Western Division. For the reasons set forth below, the Court transfers this action to the Western District of Tennessee. The Court first considers whether this case should be dismissed for improper venue. See Fed. R. Civ. P. 12(b)(3). The defendant bears the burden of establishing improper venue. United States v. Orshek, 164 F.2d 741, 742 (8th Cir.
  • Abbott-Abbvie Multiple Employer Pension Plan

    Abbott-Abbvie Multiple Employer Pension Plan

    Abbott-AbbVie Multiple Employer Pension Plan Summary Plan Description Effective January 1, 2013 This summary plan description (SPD) describes the key features of the Abbott-AbbVie Multiple Employer Pension Plan effective January 1, 2013. This booklet describes only the highlights of the plan and does not attempt to cover all administrative details. Every attempt has been made to communicate this information clearly and in easily understandable terms. Benefits and services described here apply only to those former employees and retirees eligible for benefits under the plan. The boards of directors of the companies, or when applicable, the Abbott-AbbVie Pension Plan Administrative Committee, reserve the right to modify, suspend or terminate these benefits at any time to the extent permitted by law. This SPD does not constitute a contract of employment or guarantee any particular benefit. The terms of the Abbott-AbbVie Multiple Employer Pension Plan are governed by the plan and trust documents. In case of a conflict between this SPD and those documents, the plan and trust documents will control. Table of Contents Introduction................................................................................................................................................. 1 Eligibility ..................................................................................................................................................... 1 Eligible Employees ................................................................................................................................
  • Eli Lilly and Company

    Eli Lilly and Company

    Merrimack College Merrimack ScholarWorks Honors Senior Capstone Projects Honors Program Spring 2021 Eli Lilly and Company Alyssa Ardai Follow this and additional works at: https://scholarworks.merrimack.edu/honors_capstones Part of the Business Commons Ardai 1 Written Assignment #4 Eli Lilly and Company Alyssa Ardai Bus 4402W: Strategic Analysis and Decision Making Professor Herrmann April 30, 2021 Ardai 2 Abstract Eli Lilly and Company is a pharmaceutical company that has the goal of creating new products. Eli Lilly’s products are seen in hospitals and pharmacies around the US, with the hopes of growing internationally. By having a large number of drugs in their pipeline, they can be a key player in improving multiple types of illnesses as well as help aid the aging population. The healthcare sector is always one that is high-performing. Ardai 3 Eli Lilly and Company is positioned as a pharmaceutical company, with the goal of creating high-quality medicine for every need or to take a preexisting medicine and make it better. For the past 140 years, they have been creating medicine for various causes, but are now focusing their efforts on antibody treatments for the COVID-19 pandemic, as well as different cancers and autoimmune diseases. Everything that the company does should follow its core values: integrity, excellence, and respect for people (Eli Lilly and Company - A). Eli Lilly is found in the US, Japan, Europe, and hopes to expand to the rest of the world soon. They are broken down into Endocrinology, Oncology, Immunology, Neuroscience, & Other. The company has increased revenues from $23,832.8 - $25,925.3, a consistent tax rate of 15%, expenses increasing $300k a year, accounts receivable, or a/r, decreasing as they pay less in patents and drugs go generic, consistent inventory of $120k - $140k, showing they do not keep a lot on hand, a weighted average cost of capital, or WACC, of 5.9% showing it does not hold a lot of debt, and a long term growth rate of 2.3%, showing a healthy but stable growth (Bloomberg LP, CapitalIQ 2021).
  • Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines

    Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines

    Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S.
  • Biocentury 8.15.16

    Biocentury 8.15.16

    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
  • Companies in Attendance

    Companies in Attendance

    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
  • Johnson & Johnson / Abbott Medical Optics Regulation

    Johnson & Johnson / Abbott Medical Optics Regulation

    EUROPEAN COMMISSION DG Competition Case M.8237 - JOHNSON & JOHNSON / ABBOTT MEDICAL OPTICS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 21/02/2017 In electronic form on the EUR-Lex website under document number 32017M8237 EUROPEAN COMMISSION Brussels,21.2.2017 C(2017) 1336 final In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notyfing party: Subject: Case M.8237 – Johnson & Johnson / Abbott Medical Optics Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/20041 and Article 57 of the Agreement on the European Economic Area2 Dear Sir or Madam, (1) On 17 January 2017, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Johnson & Johnson ("J&J", US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Abbott Medical Optics Inc. ("AMO", US) by way of purchase of shares3. J&J and AMO are collectively referred to as "the Parties". I. THE PARTIES AND THE OPERATION (2) J&J, headquartered in the US, is the parent company of a global group of companies which are active in the provision of pharmaceutical products, medical devices and consumer healthcare products.
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc

    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc

    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
  • 1 United States District Court for the Southern District

    1 United States District Court for the Southern District

    Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 1 of 167 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF IOWA, CENTRAL DIVISION THE STATE OF IOWA, Plaintiff, v. ABBOTT LABORATORIES, INC., AGOURON PHARMACEUTICALS, INC., JURY TRIAL REQUESTED ALPHARMA, INC., ALZA CORPORATION, AMGEN, INC., ASTRAZENECA L.P., ASTRAZENECA PHARMACEUTICALS, LP., AVENTIS BEHRING L.L.C., COMPLAINT BARR LABORATORIES, INC., BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE CORPORATION, BAYER CORPORATION, BAYER PHARMACEUTICALS CORPORATION, BEN VENUE LABORATORIES, INC., BOEHRINGER INGELHEIM CORPORATION, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY, CENTOCOR, INC., CHIRON CORPORATION, DERMIK LABORATORIES, INC., DEY, INC., DEY, L.P., ELI LILLY AND COMPANY, EMD, INC., ENDO PHARMACEUTICALS, INC., ETHEX CORPORATION, ETHICON, INC., FOREST LABORATORIES, INC., FOREST PHARMACEUTICALS, INC. GENEVA PHARMACEUTICALS, GLAXOSMITHKLINE, PLC, GLAXOWELLCOME, INC., GREENSTONE, LTD., HOECHEST MARION ROIUSSEL, INC., HOFFMAN-LAROCHE, INC., 1 Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 2 of 167 IMMUNEX CORPORATION, IVAX CORPORATION, IVAX PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICA PRODUCTS, LP, JOHNSON & JOHNSON, KING PHARMACEUTICALS, INC., KING RESEARCH AND DEVELOPMENT, MCNEIL-PPC, INC., MEDIMMUNE, INC., MERCK & CO., INC., MONARCH PHARMACEUTICALS, INC., MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., NOVARTIS PHARMACEUTICALS CORPORATION, NOVOPHARM USA, INC., ONCOLOGY THERAPEUTICS NETWORK CORP., ORTHO-MCNEIL PHARMACEUTICAL, INC.,